ScienceDaily (Apr. 16, 2008) — Using a combination of a targeted cancer-fighting agent called DFMO and a low dose of an anti-inflammatory drug, UC Irvine researchers have reduced the risk of reoccurring colorectal polyps, an early sign of colon cancer, by as much as 95 percent with fewer toxic side effects.
Read More
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment